Developer docs
API playgroundTry for free, no card

Search company profiles

Xentria, Inc.

Full company profile

uuid022pnfx

Namestring
Xentria, Inc.
Legal namestring
Xentria, Inc.
Websiteurl
xentria.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Xentria, Inc. is a private biopharmaceutical company headquartered in Chicago, Illinois, founded in 2020. The company develops therapeutics for unmet clinical needs, with its lead asset XTMAB-16 — a chimeric human-murine anti-TNF monoclonal antibody designed to suppress inflammatory pathways and granuloma formation — currently in clinical development for pulmonary sarcoidosis, a rare inflammatory disease affecting fewer than 200,000 US patients. XTMAB-16 has received Orphan Drug Designation from both the FDA (December 2020) and the EMA (November 2023), and Phase 1b/2a first-in-patient results presented at ATS 2026 demonstrated a favorable safety and tolerability profile, supporting selection of a 4mg/kg Q4W dose for continued evaluation. The company also holds an exclusive license from NYU Langone Health for a disease-modifying cardiovascular therapy and, through a partnership with Inotiv, achieved an FDA regulatory submission for biosimilar insulin aspart in April 2026, one year ahead of schedule.

Xentria operates a dual business model combining internal drug development with a venture studio called Xturnpoint, which was launched in May 2025 with $100M in deployable capital. Xturnpoint engages academic institutions and biotech researchers to identify and co-develop early-stage therapeutic programs, providing capital plus hands-on strategic guidance to bridge the funding gap between academia and industry at the preclinical and pre-IND stages. In 2025, Xturnpoint reviewed over 100 academic opportunities spanning institutions, scientific domains, and stages from early discovery through Phase II. The company describes its team as small by design, enabling focused program attention and continuity from opportunity review through program leadership.

The company's revenue mechanics are partnership-based: licensing royalties, development milestone payments, and equity stakes in co-developed programs. Customer segments are academic medical centers and research institutions, with named collaborators including NYU Langone Health, East Carolina University's Sarcoidosis Center of Excellence, and a broader portfolio of academic teams engaged through Xturnpoint. Go-to-market is sales-led and direct, relying on bilateral co-development agreements, exclusive licensing, and conference presence at events such as ATS and WASOG/AASOG rather than traditional commercial distribution. No public revenue or headcount figure is disclosed.

Short descriptiontext

Xentria is a private Chicago-based biopharmaceutical company developing therapeutics for unmet clinical needs. Its lead asset, XTMAB-16, is in clinical development for pulmonary sarcoidosis, while its Xturnpoint venture studio partners with academic institutions to advance early-stage therapeutic programs.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical development, monoclonal antibody therapy, drug development partnerships, venture studio, sarcoidosis treatment
Industry1 code
PRIMARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code1 code
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Drug Development
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Co-development partnerships and venture studio model
TypeLicensing Royalties
Description

Xturnpoint invests capital ($100M to deploy) in early-stage academic therapeutic programs. Revenue is generated through partnership agreements, milestone payments, and equity stakes in developed programs. Shared-incentive models align both sides around clearly defined milestones and expectations.

xentria.com
2Licensing and development partnerships
TypeLicensing Royalties
Description

Exclusive licensing agreements with academic institutions (e.g., NYU Langone Health) to advance disease-modifying cardiovascular therapies globally. Revenue from development milestones and commercialization rights.

xentria.com
3Biosimilar development
TypeProfessional Services
Description

Partnership with Inotiv achieving FDA regulatory submission for biosimilar insulin aspart, demonstrating milestone-based development revenue.

xentria.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Xturnpoint
Description

A venture studio launched by Xentria in 2025 to fuel early-stage therapeutic innovation, with $100M to deploy for identifying and supporting academic innovation programs.

xentria.com
Core offering1 text field

Xentria is a biopharmaceutical company that develops biologic therapeutics for unmet clinical needs, with its lead asset XTMAB-16, an anti-TNF monoclonal antibody in clinical development for pulmonary sarcoidosis. The company also operates Xturnpoint, a venture studio with $100M in deployable capital that partners with academic researchers to advance early-stage therapeutic programs from preclinical through lead-optimization stages.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • XTMAB-16 demonstrated favorable safety and tolerability profile in pulmonary sarcoidosis patients with no unexpected TNF-inhibitor class effects
+2 more records
Product overview1 text field

Xentria is a biotech company offering a dual approach to life-sciences partnerships: (1) XTMAB-16, their lead investigational biologic therapy in clinical development for pulmonary sarcoidosis, and (2) Xturnpoint, a venture studio that identifies and supports early-stage academic therapeutic programs through preclinical development and IND-enabling studies.

Product and service3 records
1XTMAB-16
CategoryInvestigational Biologic Therapy
Description

Novel chimeric human-murine anti-TNF monoclonal antibody being developed as an investigational biologic product for the treatment of pulmonary sarcoidosis with or without extra pulmonary involvement. Designed to suppress inflammatory pathways and granuloma formation by blocking TNF-alpha.

2Xturnpoint
CategoryVenture Studio Partnership Service
Description

Venture studio initiative launched in 2025 with $100M to deploy, focused on early-stage therapeutic innovation. Partners with academic institutions and researchers to advance discoveries from preclinical through lead optimization stages.

3Biosimilar Insulin Aspart (Co-development with Inotiv)
CategoryBiosimilar Pharmaceutical Product
Description

Co-developed biosimilar insulin aspart product with Inotiv, achieving FDA regulatory submission one year ahead of schedule. The biosimilar was developed through partnership with Inotiv providing contract research services supporting regulatory submissions.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Strategic partnership resulting in FDA regulatory submission for biosimilar insulin aspart achieved one year ahead of schedule. Inotiv provides contract research services supporting regulatory submissions and development programs.

2Xturnpoint
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-22
Description

Xturnpoint is Xentria's venture studio initiative launched in 2025 with $100M to deploy. It identifies early-stage therapeutic innovation opportunities across academic institutions, providing capital plus hands-on strategic guidance to bridge the funding gap between academia and industry in preclinical and pre-IND research stages.

xentria.com
3Academic Institutions (Portfolio)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Xturnpoint engaged with over 100 academic teams across institutions in 2025, reviewing opportunities spanning early discovery through Phase II. Partnerships came through tech transfer offices, consulting groups, and scientific collaborators. Focus remains on preclinical and lead-optimization stages.

xentria.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-19
Description

Exclusive licensing agreement to advance a disease-modifying cardiovascular therapy globally. Dr. David S. Park, Associate Professor of Medicine, noted Xentria's comprehensive approach from concept through preclinical testing, regulatory approvals, and clinical trials as setting it apart from other interested groups.

5East Carolina University (ECU) - Sarcoidosis Center of Excellence
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Ogugua N. Obi, Director of the Sarcoidosis Center of Excellence at ECU, presented first-in-patient study results for XTMAB-16 in sarcoidosis at ATS 2026. ECU serves as a key clinical collaborator for the Phase 1b/2a MAD study.

xentria.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotherapeutics company that builds on academic research through founded programs, closely aligned with Xentria's venture studio strategy of advancing preclinical academic discoveries.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company that operates a 'Vant' model of focused subsidiaries, sharing Xentria's venture-studio approach to developing therapeutic assets through dedicated operating units.

TypeDirect peer
Description

Clinical-stage biotherapeutics company developing immunology-focused protein therapeutics for rare inflammatory conditions, sharing Xentria's biologics platform and rare disease focus.

TypeDirect peer
Description

Commercial-stage biopharma focused on genetic and rare diseases using a hub-and-spoke co-development model with academic researchers, mirroring Xentria's academic partnership approach.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing biologics that target growth factor signaling for rare diseases, similar to Xentria's antibody-based approach in orphan indications.

TypeBroad incumbent
Description

Manufacturer of Remicade (infliximab) and Stelara, a major player in the anti-TNF and immunology biologics market relevant to Xentria's TNF-α pathway approach.

TypeBroad incumbent
Description

Manufacturer of Enbrel (etanercept), a foundational anti-TNF biologic, representing an established incumbent whose off-label use in sarcoidosis affects XTMAB-16's competitive landscape.

TypeBroad incumbent
Description

Manufacturer of Humira (adalimumab), the leading anti-TNF-α biologic, directly relevant as the incumbent benchmark in the anti-TNF space where XTMAB-16 competes.

TypeDirect peer
Description

Biopharmaceutical company focused on rare diseases with a partnership-driven development approach, comparable to Xentria's co-development model and orphan drug strategy.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing biologics for serious fibrotic diseases, comparable in scale and stage to Xentria with a similar small-team, focused-program structure.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xentria, Inc.

Biopharmaceutical Drug Developmentxentria.com

Xentria is a private Chicago-based biopharmaceutical company developing therapeutics for unmet clinical needs. Its lead asset, XTMAB-16, is in clinical development for pulmonary sarcoidosis, while its Xturnpoint venture studio partners with academic institutions to advance early-stage therapeutic programs.

What Xentria, Inc. does

Xentria, Inc. is a private biopharmaceutical company headquartered in Chicago, Illinois, founded in 2020. The company develops therapeutics for unmet clinical needs, with its lead asset XTMAB-16 — a chimeric human-murine anti-TNF monoclonal antibody designed to suppress inflammatory pathways and granuloma formation — currently in clinical development for pulmonary sarcoidosis, a rare inflammatory disease affecting fewer than 200,000 US patients. XTMAB-16 has received Orphan Drug Designation from both the FDA (December 2020) and the EMA (November 2023), and Phase 1b/2a first-in-patient results presented at ATS 2026 demonstrated a favorable safety and tolerability profile, supporting selection of a 4mg/kg Q4W dose for continued evaluation. The company also holds an exclusive license from NYU Langone Health for a disease-modifying cardiovascular therapy and, through a partnership with Inotiv, achieved an FDA regulatory submission for biosimilar insulin aspart in April 2026, one year ahead of schedule.

Xentria operates a dual business model combining internal drug development with a venture studio called Xturnpoint, which was launched in May 2025 with $100M in deployable capital. Xturnpoint engages academic institutions and biotech researchers to identify and co-develop early-stage therapeutic programs, providing capital plus hands-on strategic guidance to bridge the funding gap between academia and industry at the preclinical and pre-IND stages. In 2025, Xturnpoint reviewed over 100 academic opportunities spanning institutions, scientific domains, and stages from early discovery through Phase II. The company describes its team as small by design, enabling focused program attention and continuity from opportunity review through program leadership.

The company's revenue mechanics are partnership-based: licensing royalties, development milestone payments, and equity stakes in co-developed programs. Customer segments are academic medical centers and research institutions, with named collaborators including NYU Langone Health, East Carolina University's Sarcoidosis Center of Excellence, and a broader portfolio of academic teams engaged through Xturnpoint. Go-to-market is sales-led and direct, relying on bilateral co-development agreements, exclusive licensing, and conference presence at events such as ATS and WASOG/AASOG rather than traditional commercial distribution. No public revenue or headcount figure is disclosed.

Xentria, Inc. firmographics

Firmographics
Name
Xentria, Inc.
Legal name
Xentria, Inc.
Website
https://xentria.com
Company type
Private
Founded year
2020
Operating status
Operating
Short description
Xentria is a private Chicago-based biopharmaceutical company developing therapeutics for unmet clinical needs. Its lead asset, XTMAB-16, is in clinical development for pulmonary sarcoidosis, while its Xturnpoint venture studio partners with academic institutions to advance early-stage therapeutic programs.
Ownership category
akta.pro rank

Xentria, Inc. industry classification

Industry
Product category
Biopharmaceutical Drug Development
NAICS
Other Scientific and Technical Consulting Services (54169)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Biopharmaceutical development
  • Monoclonal antibody therapy
  • Drug development partnerships
  • Venture studio
  • Sarcoidosis treatment

Where Xentria, Inc. is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Xentria, Inc. business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Co-development partnerships and venture studio model: Xturnpoint invests capital ($100M to deploy) in early-stage academic therapeutic programs. Revenue is generated through partnership agreements, milestone payments, and equity stakes in developed programs. Shared-incentive models align both sides around clearly defined milestones and expectations.
  2. Licensing and development partnerships: Exclusive licensing agreements with academic institutions (e.g., NYU Langone Health) to advance disease-modifying cardiovascular therapies globally. Revenue from development milestones and commercialization rights.
  3. Biosimilar development: Partnership with Inotiv achieving FDA regulatory submission for biosimilar insulin aspart, demonstrating milestone-based development revenue.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Xentria, Inc. product offering

Product offering

Core offering

Xentria is a biopharmaceutical company that develops biologic therapeutics for unmet clinical needs, with its lead asset XTMAB-16, an anti-TNF monoclonal antibody in clinical development for pulmonary sarcoidosis. The company also operates Xturnpoint, a venture studio with $100M in deployable capital that partners with academic researchers to advance early-stage therapeutic programs from preclinical through lead-optimization stages.

Product overview

Xentria is a biotech company offering a dual approach to life-sciences partnerships: (1) XTMAB-16, their lead investigational biologic therapy in clinical development for pulmonary sarcoidosis, and (2) Xturnpoint, a venture studio that identifies and supports early-stage academic therapeutic programs through preclinical development and IND-enabling studies.

Differentiator

Problem solved

Functional benefit

Brands

  • Xturnpoint: A venture studio launched by Xentria in 2025 to fuel early-stage therapeutic innovation, with $100M to deploy for identifying and supporting academic innovation programs.

Products and services

  • XTMAB-16 Novel chimeric human-murine anti-TNF monoclonal antibody being developed as an investigational biologic product for the treatment of pulmonary sarcoidosis with or without extra pulmonary involvement. Designed to suppress inflammatory pathways and granuloma formation by blocking TNF-alpha.
  • Xturnpoint Venture studio initiative launched in 2025 with $100M to deploy, focused on early-stage therapeutic innovation. Partners with academic institutions and researchers to advance discoveries from preclinical through lead optimization stages.
  • Biosimilar Insulin Aspart (Co-development with Inotiv) Co-developed biosimilar insulin aspart product with Inotiv, achieving FDA regulatory submission one year ahead of schedule. The biosimilar was developed through partnership with Inotiv providing contract research services supporting regulatory submissions.

Quantifiable outcome

  • XTMAB-16 demonstrated favorable safety and tolerability profile in pulmonary sarcoidosis patients with no unexpected TNF-inhibitor class effects
  • +2 more outcomes

Companies that use Xentria, Inc.

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Xentria, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Xentria, Inc. partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and core.

  • InotivmajorStrategic or Co-development Partner · 14 April 2026Strategic partnership resulting in FDA regulatory submission for biosimilar insulin aspart achieved one year ahead of schedule. Inotiv provides contract research services supporting regulatory submissions and development programs.
  • XturnpointcoreStrategic or Co-development Partner · 22 May 2025Xturnpoint is Xentria's venture studio initiative launched in 2025 with $100M to deploy. It identifies early-stage therapeutic innovation opportunities across academic institutions, providing capital plus hands-on strategic guidance to bridge the funding gap between academia and industry in preclinical and pre-IND research stages.
  • Academic Institutions (Portfolio)coreStrategic or Co-development Partner · 1 January 2025Xturnpoint engaged with over 100 academic teams across institutions in 2025, reviewing opportunities spanning early discovery through Phase II. Partnerships came through tech transfer offices, consulting groups, and scientific collaborators. Focus remains on preclinical and lead-optimization stages.
  • NYU Langone HealthcoreStrategic or Co-development Partner · 19 December 2024Exclusive licensing agreement to advance a disease-modifying cardiovascular therapy globally. Dr. David S. Park, Associate Professor of Medicine, noted Xentria's comprehensive approach from concept through preclinical testing, regulatory approvals, and clinical trials as setting it apart from other interested groups.
  • East Carolina University (ECU) - Sarcoidosis Center of ExcellencecoreStrategic or Co-development PartnerDr. Ogugua N. Obi, Director of the Sarcoidosis Center of Excellence at ECU, presented first-in-patient study results for XTMAB-16 in sarcoidosis at ATS 2026. ECU serves as a key clinical collaborator for the Phase 1b/2a MAD study.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Xentria, Inc. competitors and assessment

Company assessment

Direct peers

  • PureTech Health: Clinical-stage biotherapeutics company that builds on academic research through founded programs, closely aligned with Xentria's venture studio strategy of advancing preclinical academic discoveries.
  • Roivant Sciences: Clinical-stage biopharmaceutical company that operates a 'Vant' model of focused subsidiaries, sharing Xentria's venture-studio approach to developing therapeutic assets through dedicated operating units.
  • aTyr Pharma: Clinical-stage biotherapeutics company developing immunology-focused protein therapeutics for rare inflammatory conditions, sharing Xentria's biologics platform and rare disease focus.
  • BridgeBio Pharma: Commercial-stage biopharma focused on genetic and rare diseases using a hub-and-spoke co-development model with academic researchers, mirroring Xentria's academic partnership approach.
  • Scholar Rock: Clinical-stage biopharmaceutical company developing biologics that target growth factor signaling for rare diseases, similar to Xentria's antibody-based approach in orphan indications.
  • Travere Therapeutics: Biopharmaceutical company focused on rare diseases with a partnership-driven development approach, comparable to Xentria's co-development model and orphan drug strategy.
  • Pliant Therapeutics: Clinical-stage biopharmaceutical company developing biologics for serious fibrotic diseases, comparable in scale and stage to Xentria with a similar small-team, focused-program structure.

Broad incumbents

  • Janssen Pharmaceuticals: Manufacturer of Remicade (infliximab) and Stelara, a major player in the anti-TNF and immunology biologics market relevant to Xentria's TNF-α pathway approach.
  • Amgen: Manufacturer of Enbrel (etanercept), a foundational anti-TNF biologic, representing an established incumbent whose off-label use in sarcoidosis affects XTMAB-16's competitive landscape.
  • AbbVie: Manufacturer of Humira (adalimumab), the leading anti-TNF-α biologic, directly relevant as the incumbent benchmark in the anti-TNF space where XTMAB-16 competes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Xentria, Inc. social profiles

Digital presence

Xentria, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xentria, Inc. leadership team

Management profile

Number of profiles

Profiles6 records

Xentria, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xentria, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xentria, Inc.

What does Xentria, Inc. do?

Xentria is a biopharmaceutical company that develops biologic therapeutics for unmet clinical needs, with its lead asset XTMAB-16, an anti-TNF monoclonal antibody in clinical development for pulmonary sarcoidosis. The company also operates Xturnpoint, a venture studio with $100M in deployable capital that partners with academic researchers to advance early-stage therapeutic programs from preclinical through lead-optimization stages.

Is Xentria, Inc. a public or private company?

Xentria, Inc. is a private company. It is classified as venture growth investor backed and is currently operating.

When was Xentria, Inc. founded?

Xentria, Inc. was founded in 2020.

Where is Xentria, Inc. based?

Xentria, Inc. is headquartered in Chicago, United States, in the North America region.

How does Xentria, Inc. make money?

Three revenue lines are on record. Co-development partnerships and venture studio model is the primary driver. The others are licensing and development partnerships and biosimilar development.

Who are Xentria, Inc.'s main competitors?

Direct peers on record are PureTech Health, Roivant Sciences, aTyr Pharma, BridgeBio Pharma, Scholar Rock, Travere Therapeutics and Pliant Therapeutics. Broad incumbents are Janssen Pharmaceuticals, Amgen and AbbVie.

Does Xentria, Inc. have an API?

No public API is recorded for Xentria, Inc..

What industry is Xentria, Inc. in?

Xentria, Inc.'s product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAAAMAB, Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy). Its NAICS code is 54169 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireExpanding Horizons: Xentria Achieves Milestone Success with Biosimilar DevelopmentXentria, Inc., a Chicago-based clinical-stage biotherapeutics company, announced the operational expansion of multiple clinical trials in 2025 across 11 countries and 3 regions, building on 5 biosimilar clinical trials initiated in 2024 with completed enrollment in 2 of those trials. The company's lead asset XTMAB-16, an anti-TNFα monoclonal antibody for pulmonary sarcoidosis, advanced with trial operations opened in the United Kingdom and regulatory approval received in the European Union, while up to 6 additional biosimilar studies are planned for 2025. Xentria positioned the milestone as validation of its operational growth and strategic capacity to lead challenging drug development in the biosimilars space.XentriaExpanding Horizons: Xentria Achieves Milestone Success with Biosimilar DevelopmentXentria announced the operational expansion of multiple clinical trials across 11 countries in 2025, building on five biosimilar trials initiated in 2024. The company is advancing its lead asset, XTMAB-16, a monoclonal antibody for pulmonary sarcoidosis, which received approval to proceed in the European Union after opening operations in the United Kingdom.NatureXentria: redefining collaborative approaches to advance R&DXentria, a Chicago-based biotech, uses collaborative R&D with partners to advance drug candidates, exemplified by its TNF-α antibody XTMAB-16 for pulmonary sarcoidosis. The company used in vitro and pharmacokinetic modeling to guide dosing and partnered with Meitheal Pharmaceuticals for a North American licensing deal in 2023.